HI
NRXP icon

Harbour Investments’s NRX Pharmaceuticals NRXP Stock Holding History

Harbour Investments’s Portfolio NRXP Stock Details NRXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-47
Closed -$79 – 3560
2024
Q3 		$79 Hold
47
– – ﹤0.01% 3325
2024
Q2 		$115 Buy
+47
New +$167 ﹤0.01% 3198

Other funds holding NRXP

AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OWMIAS
One Wealth Management Investment & Advisory Services Miami Beach, Florida $95.3M AUM 25.31% 1-Year Est. Return

Harbour Investments's NRXP Position: Q4 2024 in Review

Harbour Investments sold out of NRX Pharmaceuticals (NRXP) in Q4 2024, closing a stake of 47 shares — an estimated $79 sold.

Harbour Investments first reported a position in NRXP in Q2 2024 and held it in 2 quarters. The position peaked at $115 in Q2 2024. 25 funds tracked by Wall St. Rank hold NRXP as of Q4 2024.

  • Harbour Investments reported no remaining NRX Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Harbour Investments sold 47 NRX Pharmaceuticals shares in Q4 2024, an estimated $79.
  • Harbour Investments first reported a position in NRX Pharmaceuticals in Q2 2024 and held it in 2 quarters.
  • Harbour Investments's NRX Pharmaceuticals position peaked at $115 in Q2 2024.
  • 25 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q4 2024.

Based on Harbour Investments's 13F filing for Q4 2024, filed 10 Feb 2025.